Kairos Pharma (NYSEAMERICAN:KAPA) Stock Price Down 0.1% – What’s Next?

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) traded down 0.1% on Friday . The company traded as low as $0.6402 and last traded at $0.6644. 126,041 shares were traded during trading, a decline of 31% from the average session volume of 181,725 shares. The stock had previously closed at $0.6648.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reiterated a “buy” rating and set a $9.00 price target on shares of Kairos Pharma in a report on Wednesday, November 19th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Kairos Pharma presently has a consensus rating of “Buy” and an average price target of $8.33.

Kairos Pharma Stock Down 0.1%

The company has a market cap of $13.83 million, a price-to-earnings ratio of -2.14 and a beta of 2.28. The stock’s 50-day simple moving average is $0.79 and its 200 day simple moving average is $1.02.

Kairos Pharma (NYSEAMERICAN:KAPA) last announced its earnings results on Friday, November 14th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Kairos Pharma

Several institutional investors have recently bought and sold shares of the company. FNY Investment Advisers LLC acquired a new stake in shares of Kairos Pharma during the third quarter worth about $27,000. XTX Topco Ltd purchased a new stake in Kairos Pharma during the 2nd quarter worth approximately $44,000. Finally, Two Sigma Investments LP acquired a new stake in Kairos Pharma during the 3rd quarter worth approximately $54,000.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.